Kim P. C. Kuypers

TL;DR: It is concluded that ayahuasca produces sub-acute and long-term improvements in affect and cognitive thinking style in non-pathological users, highlighting the therapeutic potential of Ayahuasca in the treatment of mental health disorders, such as depression.

TL;DR: The present data suggest that ayahuasca increases psychological flexibility, which may facilitate psychotherapeutic interventions and support clinical trial initiatives.

TL;DR: The lack of interaction indicated that the CNS stimulant effects of MDMA were never sufficient to overcome alcohol-induced impairment of impulse control or risk-taking behavior.

TL;DR: It is concluded that while most anecdotal reports focus on the positive experiences with microdosing, future research should also focus on potential risks of (multiple) administrations of a psychedelic in low doses, and (pre)clinical studies including biological as well as cognitive parameters have to be conducted to shed light on the potential negative consequencesmicrodosing could have.

TL;DR: It is demonstrated that psilocybin induced region-dependent alterations in glutamate, which predicted distortions in the subjective experience of one’s self (ego dissolution), which may provide a neurochemical basis for therapeutic effects as witnessed in ongoing clinical trials.